loading page

Renal Denervation for the Treatment of Ventricular Arrhythmias: A Systematic Review and Meta-Analysis
  • +5
  • Gabriela Prado,
  • Felix Mahfoud,
  • Renato Lopes,
  • Dalmo Moreira,
  • Rodolfo Staico,
  • Lucas Damiani,
  • Christian Ukena,
  • Luciana Armaganijan
Gabriela Prado
Instituto Dante Pazzanese de Cardiologia
Author Profile
Felix Mahfoud
Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes
Author Profile
Renato Lopes
Duke University
Author Profile
Dalmo Moreira
Instituto Dante Pazzanese de Cardiologia
Author Profile
Rodolfo Staico
Instituto Dante Pazzanese de Cardiologia
Author Profile
Lucas Damiani
Hospital do Coracao
Author Profile
Christian Ukena
Saarland University Hospital and Saarland University Faculty of Medicine
Author Profile
Luciana Armaganijan
Instituto Dante Pazzanese de Cardiologia
Author Profile

Abstract

Introduction Ventricular arrhythmias (VAs) are a major cause of morbidity and mortality in patients with heart disease. Recent studies evaluated the effect of renal denervation (RDN) on the occurrence of VAs. We conducted a systematic review and meta-analysis to determine the efficacy and safety of this procedure. Methods and results A systematic search of the literature was performed to identify studies that evaluated the use of RDN for the management of VAs. Primary outcomes were reduction in the number of VAs and implantable cardioverter-defibrillator (ICD) therapies. Secondary outcomes were changes in blood pressure and renal function. Ten studies (152 patients) were included in the meta-analysis. RDN was associated with a reduction in the number of VAs, ATP (antitachycardia pacing), ICD shocks and overall ICD therapies of 3.53events/patient/month (95%CI=-5.48 to -1.57), 2.86events/patient/month (95%CI=-4.09 to -1.63), 2.04events/patient/month (95%CI=-2.12 to -1.97), and 2.68events/patient/month (95%CI=-3.58 to -1.78), respectively. Periprocedural adverse events occurred in 1.23% of patients and no significant changes were seen in blood pressure or renal function. Conclusions In patients with refractory VAs, RDN was associated with a reduction in the number of VAs and ICD therapies, and was shown to be a safe procedure. KEYWORDS: Renal denervation, ventricular arrhythmias, implantable cardioverter-defibrillator, antitachycardia pacing, ICD shocks.

Peer review status:Published

03 Nov 2020Submitted to Journal of Cardiovascular Electrophysiology
04 Nov 2020Submission Checks Completed
04 Nov 2020Assigned to Editor
05 Nov 2020Reviewer(s) Assigned
08 Dec 2020Review(s) Completed, Editorial Evaluation Pending
10 Dec 2020Editorial Decision: Revise Minor
08 Jan 20211st Revision Received
09 Jan 2021Assigned to Editor
09 Jan 2021Submission Checks Completed
09 Jan 2021Reviewer(s) Assigned
31 Jan 2021Review(s) Completed, Editorial Evaluation Pending
01 Feb 2021Editorial Decision: Revise Minor
06 Feb 20212nd Revision Received
15 Feb 2021Submission Checks Completed
15 Feb 2021Assigned to Editor
15 Feb 2021Reviewer(s) Assigned
22 Feb 2021Review(s) Completed, Editorial Evaluation Pending
23 Feb 2021Editorial Decision: Accept
16 Mar 2021Published in Journal of Cardiovascular Electrophysiology. 10.1111/jce.15004